Product
SGR-2921
1 clinical trial
2 indications
Indication
Acute Myeloid LeukemiaIndication
Myelodysplastic SyndromesClinical trial
A First-In-Human, Phase 1, Dose Escalation Study of SGR-2921 as Monotherapy In Subjects With Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeStatus: Recruiting, Estimated PCD: 2025-12-01